Regarding Purdue/Gzmo deal:
FRAMINGHAM, Mass. and Stamford, Conn., Oct 18, 2000 /PRNewswire via COMTEX/ -- Genzyme Molecular Oncology (Nasdaq: GZMO chart, msgs) and Purdue Pharma L.P.,... This agreement has the potential to provide Genzyme Molecular Oncology with more than $330 million in up front and milestone payments from Purdue Pharma if all 20 selected antigens are ultimately developed and approved for sale.
What does the phrase "selected antigens are ultimately developed and approved for sale." imply? does Purdue only pay if they receive FDA approval for products using gzmo antigens or does gzmo receives payment upon transfering antigen to Purdue regardless of commercial outcome? If it is the latter scenario this stock doubles the first time Purdue pays over $15m (my guess, $300m/20antigens)
Please add this question to your homework! -g- (think i will email gzmo & see if they respond)
Have also been reflecting on how 'easy' it has been to make money in bio this year. Most of it seems to be timing -- confluence of science & computing within bio industry; and also influence of internet/information on investing industry. Lots of excess funds pouring into US markets has certainly helped as well. Having been invested in a few bios for many years (sepr,gene,gztc,pre DNA genetech) I am familiar with bio madness. This year does seem different, especially given the scale of money inflows. All I know is that I am glad to be here for the first inning because the rest of the game may very well be alot more demanding than this novice can handle. Harmon's mantra of this now being a stock pickers niche rings true to me. But hey, at least guys like us got to connect with a few warm up pitches -g-. |
